Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Weber, Jeffrey S; Poretta, Tayla; Stwalley, Brian D; Sakkal, Leon A; Du, Ella X; Wang, Travis; Chen, Yan; Wang, Yan; Betts, Keith A; Shoushtari, Alexander N

Weber, Jeffrey S; Poretta, Tayla; Stwalley, Brian D; Sakkal, Leon A; Du, Ella X; Wang, Travis; Chen, Yan; Wang, Yan; Betts, Keith A; Shoushtari, Alexander N.

Afiliación

Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. jeffrey.weber@nyulangone.org.
Poretta T; Bristol Myers Squibb, Princeton, NJ, USA.
Stwalley BD; Bristol Myers Squibb, Princeton, NJ, USA.
Sakkal LA; Bristol Myers Squibb, Princeton, NJ, USA.
Du EX; Analysis Group, Inc., Los Angeles, CA, USA.
Wang T; Analysis Group, Inc., Los Angeles, CA, USA.
Chen Y; Analysis Group, Inc., Los Angeles, CA, USA.
Wang Y; Analysis Group, Inc., Los Angeles, CA, USA.
Betts KA; Analysis Group, Inc., Los Angeles, CA, USA.
Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cancer Immunol Immunother ; 72(4): 955, 2023 Apr.

Article en En | MEDLINE | ID: mdl-36538061

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google